PAION AG operates as a pharmaceutical company, which engages in the development of drugs to be used in out-patient and hospital-based sedation, anesthesia, and critical care services. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 64 full-time employees. The company went IPO on 2005-02-11. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Follow-Up Questions
Paion AG의 CEO는 누구입니까?
Mr. Gregor Siebert은 2022부터 회사에 합류한 Paion AG의 Chairman of the Management Board입니다.
PAIOF 주식의 가격 성능은 어떻습니까?
PAIOF의 현재 가격은 $0.01이며, 전 거래일에 decreased 0% 하였습니다.
Paion AG의 주요 사업 주제나 업종은 무엇입니까?
Paion AG은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Paion AG의 시가총액은 얼마입니까?
Paion AG의 현재 시가총액은 $71300입니다
Paion AG는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 7명의 분석가가 Paion AG에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 5명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
